Skip to main content
OpenTrials
Withdrawn

NCT Number: NCT05589012

Evaluation of Viral Replication by Tonate Virus (TONV) and Zika Virus (ZIKV), Within an ex Vivo Trophoblast and Placental Model

Prospective, non-interventional study carried out after culturing placental trophoblastic tissue ex vivo and infection with Zika and Tonate

Why the study stopped: Withdrawal by the investigators
Withdrawn

Looking for future studies?

Notify Me

Key information

About this study

The analysis will relate for each virus studied + control + favipiravir to 1 placenta in the 1st trimester and 1 placenta at term.

2 experiments per virus will be planned.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient over 18 years old
  • Singleton pregnancy of normal course, at term, birth by caesarean section OR
  • Trophoblast from Voluntary Termination of Pregnancy (IVG), after endo-uterine aspiration

Exclusion criteria

  • Need for pathological, genetic or bacteriological examination of the placenta
  • Multiple pregnancy
  • HBV+ (Hepatitis B positive), HCV+ (Hepatitis C positive) , known CMV seroconversion during pregnancy (CytoMégaloVirus)
  • Immunosuppression (drugs, corticosteroids, etc.)
  • Diabetes
  • Pre eclampsia
  • Intrauterine growth retardation (IUGR),
  • Vascular or placental pathology.
  • Refusal to participate
  • Patient under guardianship / curatorship / security measure
  • Patient under AME (state medical aid)

Treatment and study plan

Cell line and virus

Biological

C6/36 cells will be cultured in L15 culture medium (Leibovitz's L-15 medium), supplemented with 5% FBS (Fetal Bovine Serum) and 1% penicillin/streptomycin at 28°C in a humidified atmosphere containing 5% C02. ZIKV and TONV will be expanded and titrated using C6/36 cells. The viral stock will be aliquoted in 100 µL aliquots and stored at -80°C.

Infection of human placental culture explants

Biological

Placental tissues will be handled within one hour of delivery. The chorionic villi will be dissected into 5mm sections and the tissues washed abundantly, minimum 3 times with a standard culture medium (RPMI-1640 supplemented with 10% heat-inactivated fetal calf serum (FCS), 1% L-Glutamine and 1% Penicillin/Streptomycin) to remove maternal blood, membranes and blood clots.

Collagen gel sponges will be placed in 6-well plate wells containing 3mL of culture medium (RPMI-1640 supplemented with 15% heat-inactivated fetal bovine serum (FCS), 1% Penicillin/streptomycin, 0 1% Gentamycin, 1% Amphotericin B, 1% L-Glutamine, 1% non-essential amino acid, 1% sodium pyruvate) per well. Chorionic villi will be dissected into 5mm sections and placed on top of collagen gel sponges at the interface between culture medium and air.

Determination of viral load in tissues by qRT-PCR

Biological

The tissues will be lysed by mechanical disruption in a lysis buffer + 4%TCEP (Tris(2-carboxyethyl)phosphine hydrochloride) (Machery-Nagel ref: 740395.107) with the Precellys system. The lysed tissues will be diluted in 100 mg/mL of Macherey-Nagel lysis buffer, aliquoted and stored at -80°C until extraction. Total RNA will be extracted in duplicate using the Nucleospin 96 RNA Core kit (Macherey Nagel ref: 740466.4), following the supplier's instructions.

Standard samples, controls and ZIKV and TONV viral RNA will be extracted and tested in parallel under the same conditions. The extracted RNA will be subjected to reverse transcriptase, using the Superscript One-Step RT-qPCR kit (Invitrogen ref: 11732088) according to the manufacturer's recommendations, with a probe and primer specific for ZIKV and TONV.

Primary outcomes

  1. To assess the replication potential of TONV and ZIKV after placenta infection ex vivo.

    Time frame: inclusion

    Determine the viral load (RT-qtPCR) of TONV and ZIKV after placenta infection, ex vivo in RNA copies/mL

Secondary outcomes

  1. Validate the ex vivo placental model for TONV.

    Time frame: Inclusion

    Analysis of viral load in placental explants for TONV in RNA copies/mL

  2. Compare viral infection of the placenta at different terms of pregnancy (first trimester and term).

    Time frame: first trimester

    Analysis of the viral load according to the term in RNA copies/mL

  3. Compare viral infection of the placenta at different terms of pregnancy (first trimester and term).

    Time frame: first trimester

    Analysis of gene expression of the different cytokines according to the term in RNA copies/mL

  4. Compare viral infection of the placenta at different terms of pregnancy (first trimester and term).

    Time frame: first trimester

    Analysis of the histological lesions according to the term in RNA copies/mL

  5. Compare viral infection of the placenta at different terms of pregnancy (first trimester and term).

    Time frame: term

    Analysis of the viral load according to the term in RNA copies/mL

  6. Compare the placental infection of TONV versus ZIKV.

    Time frame: inclusion

    Analysis of viral load depending on the virus (ZIKV vs TONV) in RNA copies/mL

  7. Compare the placental infection of TONV versus ZIKV.

    Time frame: inclusion

    Analysis of gene expression of different cytokines depending on the virus (ZIKV vs TONV) in RNA copies/mL

  8. Compare the placental infection of TONV versus ZIKV.

    Time frame: inclusion

    Analysis of histological lesions depending on the virus (ZIKV vs TONV) in RNA copies/mL

  9. Highlight the cellular targets of TONV.

    Time frame: inclusion

    Histological analysis and labeling of TONV cells in RNA copies/mL

  10. Highlight the cellular targets of TONV.

    Time frame: inclusion

    Histological analysis and labeling of placental cells in RNA copies/mL

Sponsors and collaborators

Lead sponsor

Assistance Publique - Hôpitaux de Paris

Other

Registry information

Acronym: ZITOPEx

Important dates

Study start
2023
Primary completion
2024
Study completion
2024
First posted
Oct 21, 2022
Registry last updated
Aug 12, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.